PR Newswire Clinical TrialsOriginal article
A $10 Generic Cut LDL Cholesterol by 53%. Why Are Employers Being Pushed Toward $700-a-Month Drugs?
Data ReadoutpositiveGeneric LDL cholesterol drugezetimibePCSK9 inhibitorsPositive
AI Analysis
Summary
Research from TOWARD Health demonstrates that a $10 generic drug achieved 53% LDL cholesterol reduction, nearly three times greater than conventional ezetimibe and comparable to PCSK9 inhibitor trials, raising questions about pharmaceutical pricing strategies.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Generic drug reduced LDL cholesterol by 53%, nearly three times the conventional ezetimibe response and within the range reported in PCSK9 inhibitor trials
Importance:4/10
Sentiment:
0.60
cholesterolgeneric drugLDL reductionresearchcost-effectiveness
Read the original article
Published by PR Newswire Clinical Trials on August 25, 2026 3:45 PM